Related Experiment Videos
Sendai virus for gene therapy and vaccination
Uta Griesenbach1, Makoto Inoue, Mamoru Hasegawa
1Imperial College London, NHLI, UK. u.griesenbach@imperial.ac.uk
Current Opinion in Molecular Therapeutics
|August 27, 2005
Summary
Sendai virus (SeV) is a versatile RNA vector with demonstrated therapeutic potential in preclinical studies for various diseases and vaccination applications. Recent advancements in SeV vectorology continue to enhance its utility in gene therapy and immunization strategies.
Area of Science:
- Virology
- Molecular Biology
- Gene Therapy
Background:
- Sendai virus (SeV), or hemagglutinating virus of Japan (HVJ), is a paramyxovirus known for its membrane fusion capabilities.
- HVJ-liposomes, derived from SeV, have been used since the 1980s.
- Advances in reverse genetics have led to non-transmissible recombinant SeV vectors for cytoplasmic expression.
Purpose of the Study:
- To review the use of SeV for gene therapy and vaccination since 2004.
- To discuss recent improvements in SeV vector technology.
Main Methods:
- Review of preclinical studies and published data on SeV applications.
- Analysis of advancements in SeV vector construction and design.
Main Results:
- SeV vectors show therapeutic potential in preclinical models for airways, brain, ischemic diseases, and tumors.
- SeV vectors have been explored for vaccination purposes.
- Recent improvements have refined SeV vectorology.
Conclusions:
- Recombinant SeV vectors offer significant potential for gene therapy and vaccination.
- Ongoing improvements in SeV vector technology are expanding its applications.